Fig. 2
From: PRMT3 methylates HIF-1α to enhance the vascular calcification induced by chronic kidney disease
PRMT3 inhibitor SGC707 inhibits CKD-induced vascular calcification in vivo
C57BL/6 mice were received a diet containing 0.8% phosphorus and 0.2% adenine for six weeks, followed by a diet containing 1.8% phosphorus and 0.2% adenine for four weeks. Meanwhile, mice were intraperitoneally injected with 10 mg/kg SGC707. The levels of (A) creatinine, (B) BUN, and (C) phosphorus were elevated in the serum of mice, which were reduced by SGC707 treatment. (D) Pathological injury was assessed with H&E staining. Scar bar is 100 μm. (E) Aorta calcification was evaluated by Alizarin Red S. Scar bar is 50 μm. (F) Alizarin Red S-stained aorta. Scar bar is 0.5 cm. (G) Calcium content of aorta. (H) ALP content. (I) Western blot bands of α-SMA, SM22α, SMMHC, OPN, OCN, GLUT1, and PKM2. Data is represented as mean ± SD. p < 0.05, p < 0.01 vs. CKD. ALP: alkaline phosphatase; α-SMA: alpha smooth muscle actin; CKD: chronic kidney disease; GLUT1: glucose transporter type 1; H&E: hematoxylin and eosin; HIF-1α: hypoxia inducible factor 1 subunit alpha; OPN: osteopontin; OCN: osteocalcin; PKM2: pyruvate kinase M1/2; PRMT3: protein arginine methyltransferase 3; SM22α: smooth muscle 22 alpha; SMMHC: smooth muscle myosin heavy chain